Browsing Category
Pharma Industry News
4730 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Jacobio Pharma secures $2bn global licensing agreement with AstraZeneca for JAB-23E73
Jacobio Pharma’s $2B global licensing deal with AstraZeneca could reshape KRAS inhibitor strategy in oncology. Read the full breakdown of the partnership now.
Can Rubraca really replace docetaxel in prostate cancer? FDA just said yes
Rubraca becomes first PARP inhibitor approved before chemo in BRCA+ prostate cancer. Find out how TRITON3 data is reshaping treatment strategy.
Can AI-guided delivery platforms reshape CNS drug development? Inside the Mercury Bio and Meta-Flux alliance
Mercury Bio and Meta-Flux are teaming up to tackle Parkinson's and Alzheimer's with AI-powered simulation and next-gen delivery. Can this reshape CNS drug development?
Is Alvotech about to reshape Europe’s anti-TNF market with its Simponi biosimilar?
Alvotech and STADA launch Europe’s first Simponi biosimilar, Uzpruvo. Find out how this shifts competition in the €1B+ anti-TNF therapy market.
GSK offloads Human Genome Sciences: what’s next for Samsung Biologics’ global ambitions?
Samsung Biologics acquires Human Genome Sciences from GSK for $280M, gaining its first U.S. biologics plant. Find out what this move means for global CDMO strategy.
Lilly’s oral GLP-1 orforglipron sustains weight loss after injectables in pivotal Phase 3 trial
Lilly’s orforglipron helped patients maintain weight loss after injectable GLP-1s in a Phase 3 trial. Find out how this could reshape obesity treatment paths.
Pfizer signs five-year marketing deal with Cipla for Corex, Dolonex, and Neksium in India
Pfizer Limited has partnered with Cipla Limited to market and distribute four major brands in India. Find out what this means for both companies and the industry.
How Hansa Biopharma’s imlifidase could redefine access for hardest-to-match transplant candidates
Hansa Biopharma seeks FDA approval for imlifidase to expand transplant eligibility in high-risk ESRD patients. See what this filing means for U.S. access.
Avacta Therapeutics (AIM: AVCT) reports 90% disease control rate in faridoxorubicin salivary gland cancer trial
Avacta Therapeutics’ AVA6000 trial shows a 90% disease control rate in salivary gland cancer. Find out how its tumor-activated approach could reshape chemotherapy.
From Medtronic to the market: What MiniMed’s IPO means for CGM and insulin pump competition
Medtronic files IPO for MiniMed, its diabetes device business. Find out what this spin-off could mean for the future of CGM and insulin delivery tech.